Abstract Library

#3842 Long response to 177-Lu DOTATATE of a long malignant metastatic pheochromocytoma survivor

Introduction: A 64-year-old man was admitted on November 2010 with a CT-scan showing a 9cm right adrenal mass and high 24-hour urine metanephrins and cathecolamins. The mass was resected in December 2010 confirming a pT3N1 pheochromocytoma (PHEO). In May 2013 he presented a local recurrence that was resected proving metastatic lymphatic tissue. On May 2014 biochemical progression preceded a CT scan showing retroperitoneal lymphadenophaties with MIBG uptake. He was then treated with 131I-MIBG (two cycles) until May 2015, having biochemical and radiological response. After lymphatic tumor progression in January 2018, he received two more cycles of 131I-MIBG therapy (cumulative dose 800mCi) with proven refractory disease. He continued follow-up until two new abdominal masses appeared in October 2020. A high uptake in the 99Tc octreotide scintigraphy showed somatostatin receptors expression. The patient refused to participate in a clinical trial, so he was treated off-label with 177Lu-DOTATATE (800mCi) four doses from February to July 2021 achieving a near-complete response.

Conference:

Presenting Author: Martin Fernandez de Soignie A

Authors: Martin Fernandez de Soignie A, Martinez Moreno E, Antón-Pascual B, Pantin Gonzalez C, Sanchez Baños N,

Keywords: pheochromocytoma, 177-Lutetium,

#3421 131I-MIBG scintigraphy in the diagnosis of pheochromocytoma: Retrospective study of 50 cases

Introduction: Pheochromocytoma is a rare tumor of the adrenal medulla. Its exploration with Metaiodobenzylguanidine (MIBG) scintigraphy is one of the current standard diagnostic procedures.

Conference:

Presenting Author:

Authors: Ghomari C, Tahraoui Z, Merad S, Medjahedi A,

Keywords: 131I-MIBG, pheochromocytoma, specificity,

#662 Sequlae and Survivorship in Neuroendocrine Patients Treated with 131I-MIBG

Introduction: Radionuclide therapy in the form of 131I-MIBG has been in therapeutic use since the 1980s. Newer modalities are emerging for the treatment of neuroendocrine and chromaffin cell tumors, but many of these do not yet have adequate long-term follow-up to determine longer term efficacy and sequelae.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Sze C, Grossman A, Amendra D, Shieh S, Plowman N,

Keywords: neuroendocrine tumors, chromaffin cell tumors, radionuclide therapy, survival, long-term sequelae ,

#142 The role of 18F DOPA-PET in a case of malignant pheochromcytoma

Introduction: Pheocromocytoma is a rare tumor arising from chromaffin cells of adrenal medullary or extra adrenal paraganglionic tissue. Histological criteria cannot differentiate benign from malignant pheocromocytomas. The diagnosis of a malignant pheocromocytoma requires local invasion, recurrence and documented metastatic disease. The radionuclide scanning (123I - 131I-MIBG) is a fundamental diagnostic tool used to confirm the biochemical and radiological diagnosis of pheochromocytoma. In fact, MIBG scanning may confirm that the visualised lesion in an adrenal gland is indeed a pheochromocytoma and detect extra-adrenal paraganglionic tissue. However, MIBG scans are negative in around 15% of benign pheochromocytomas and in up to 50% of malignant ones. Other radionuclide techniques (18FDG-PET, 18F-DOPA-PET, 18F-FDA-PET) have been successfully used in investigation of pheochromocytomas. 18F-DOPA-PET and 18F-FDA-PET have been reported to be highly sensitive and specific for benign pheochromocytomas, while 18FDG-PET can be useful for malignant lesions with higher metabolic activity.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: De Marinis L

Authors: Lugli F, Fusco A, Bianchi A, Iacovazzo D, Mormando M,

Keywords: malignant pheochromocytoma, 18F-DOPA-PET, MIBG,